Johnson & Johnson Collaborates with Sail Biomedicines for CAR-T Therapy Expansion
Johnson & Johnson (JNJ) has entered into a collaboration deal with Sail Biomedicines to develop in vivo CAR-T therapies targeting immune-mediated diseases. The partnership includes an initial $785 million payment from JNJ, plus up to $140 million for milestones and an option to acquire the company for $2.58 billion. This move is part of Johnson & Johnson's strategy to expand its next-generation CAR-T portfolio beyond cancer treatment. The global CAR-T therapy market is expected to grow significantly, from $2.69 billion in 2022 to $35.9 billion by 2032 at a compound annual growth rate (CAGR) of 28.5%. JNJ's existing flagship product Carvykti has already gained traction for treating multiple myeloma and is approved in over a dozen markets. Bristol-Myers Squibb (BMY), another major player, holds strong positions with its Breyanzi franchise but faces competition as both companies aim to diversify into non-cancer diseases. JNJ also appears more attractive from an investment standpoint due to stronger hedge fund interest and lower short seller exposure.
Topics: CAR-T therapies Johnson & Johnson strategy pharmaceutical partnerships